Price T Rowe Associates Inc. MD Sells 27,105 Shares of Ascendis Pharma A/S $ASND

Key Points

• Price T Rowe Associates Inc. MD reduced its stake in Ascendis Pharma A/S by 1.2%, owning 2,256,102 shares valued at approximately $351.6 million as of its latest SEC filing.
• Ascendis Pharma's recent earnings report showed an EPS of ($0.93), surpassing analyst expectations of ($1.42) and generating $216.28 million in revenue against projected $163.17 million.
• Equities research analysts maintain a strong outlook for Ascendis Pharma, with the stock receiving a majority of Buy ratings and an average price target of $243.36.

Price T Rowe Associates Inc. MD decreased its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 1.2% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 2,256,102 shares of the biotechnology company's stock after selling 27,105 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 3.70% of Ascendis Pharma A/S worth $351,637,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. RA Capital Management L.P. boosted its stake in Ascendis Pharma A/S by 4.1% in the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after purchasing an additional 402,316 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in shares of Ascendis Pharma A/S by 12.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company's stock valued at $475,970,000 after acquiring an additional 328,278 shares during the last quarter. Vestal Point Capital LP boosted its position in shares of Ascendis Pharma A/S by 108.0% during the 4th quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company's stock valued at $71,588,000 after acquiring an additional 270,000 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Ascendis Pharma A/S by 4.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock valued at $602,910,000 after acquiring an additional 193,688 shares during the last quarter. Finally, Soleus Capital Management L.P. bought a new stake in shares of Ascendis Pharma A/S during the 4th quarter valued at about $19,824,000.

Analyst Ratings Changes

A number of brokerages recently weighed in on ASND. Wedbush raised their price objective on Ascendis Pharma A/S from $212.00 to $220.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Oppenheimer reissued an "outperform" rating and set a $224.00 price objective (up from $215.00) on shares of Ascendis Pharma A/S in a report on Friday, June 13th. Bank of America raised their price objective on Ascendis Pharma A/S from $201.00 to $216.00 and gave the company a "buy" rating in a report on Monday, June 9th. Cantor Fitzgerald lifted their price target on Ascendis Pharma A/S from $200.00 to $203.00 and gave the stock an "overweight" rating in a research note on Friday, August 8th. Finally, Morgan Stanley initiated coverage on Ascendis Pharma A/S in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $250.00 price target on the stock. Fifteen analysts have rated the stock with a Buy rating, According to MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of "Buy" and a consensus target price of $243.36.

Ascendis Pharma A/S Trading Up 0.5%

Shares of ASND stock traded up $0.93 during trading hours on Thursday, reaching $193.94. The company's stock had a trading volume of 314,628 shares, compared to its average volume of 491,811. The stock has a market capitalization of $11.87 billion, a P/E ratio of -37.59 and a beta of 0.41. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $199.99. The firm's fifty day simple moving average is $179.38 and its 200 day simple moving average is $164.88.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping analysts' consensus estimates of ($1.42) by $0.49. The business had revenue of $216.28 million during the quarter, compared to the consensus estimate of $163.17 million. As a group, equities research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.